Page 106 - Mployee Wellness Programs News Today

Hospitals and outpatient treatment centers in at least three states are struggling to get their systems back online following a ransomware attack waged last week against parent company Prospect Medical Holdings. Some of these facilities have partially or completely halted patient care.

Talkiatry and NOCD are teaming up to improve care for patients with obsessive-compulsive disorder. Talkiatry specializes in medication management, while NOCD specializes in Exposure and Response Prevention therapy.

Izervay, a drug developed by Astellas Pharma subsidiary Iveric Bio, is now the second approved therapy for the degenerative vision-loss disorder geographic atrophy. The regulatory decision comes as safety concerns emerge around the first therapy for the disease, an Apellis Pharmaceuticals product.

Clinical trial design will be one of the topics discussed at the upcoming INVEST Digital Health conference in Dallas on October 26. THREAD Clinical Trial Design Director Noah Goodson highlighted some of the milestones the sector has seen in recent years.

Many Medicaid enrollees are not receiving the information they need from health plans during the return to Medicaid renewals, a new survey shows. Older Medicaid enrollees are especially struggling.

Long Covid continues to afflict patients and mystify clinicians. The National Institutes of Health is trying to identify potential treatments and it is launching a series of clinical trials that will assess a wide range of therapeutic interventions.

We need to create a care model that doesn’t treat menopause as some separate gray area of women’s health where doctors are unequipped and patients are left to their own devices to figure it out.

Sage Therapeutics’ Zurzuvae is the biotech’s second FDA approved product for postpartum depression, following the 2019 nod for IV-infused Zulresso. But in a blow to the multi-billion dollar partnership between Sage and Biogen, Zurzuvae did not win an additional approval in major depressive disorder.

Virtual care company TytoCare recently raised $49 million in growth financing, taking its total funding to date to $205 million. CEO Dedi Gilad declared that his company was founded to solve a fundamental problem with traditional telehealth services: people do not trust them, so they do not use them.

Hims & Hers can now provide treatment to men for cardiovascular issues, the company recently announced. This treatment combines sexual health and heart health together in a single pill.